This page shows the latest neurogenics news and features for those working in and with pharma, biotech and healthcare.
Gains access to pipeline with potential for development in ‘neurogenic’ indications. ... These receptors seem to become more common after nerve injury or inflammation, and drugs that block them are thought to have potential in a broad range of
Chelsea's marketed product - Northera (droxidopa) - was given a green light by the US FDA in February as the first drug specifically approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a
The Food and Drug Administration (FDA) backed Northera capsules (droxidopa) to treat neurogenic orthostatic hypotension (NOH), a chronic drop in blood pressure that is found in patients with Parkinson's disease, ... People with neurogenic orthostatic
The regulator's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16 to 1 in favour of the approval of Northera (droxidopa) to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients ... with an underlying neurogenic disorder,
A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO). ... NDO results from neurogenic bladder, due to stable sub-cervical spinal cord injury (SCI) or multiple sclerosis (MS).
The company is currently conducting phase II clinical trials as part of an effort to win marketing approval for neurogenic and idiopathic overactive bladder.
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
in development for the treatment of neurogenic conditions, such as chronic cough.
825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).
Chelsea has the recently FDA-approved droxidopa, the first and only symptomatic treatment for neurogenic orthostatic hypotension ready for launch later this year.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...